Key result
Cangrelor provides fast platelet inhibition during complex PCI, but may cause a potential rebound effect at the end of its infusion before the oral P2Y12 effect is achieved.
Why the study?
Does cangrelor provide fast platelet inhibition in patients with acute or chronic coronary syndrome undergoing complex PCI?
Cohort
No
Does cangrelor provide fast platelet inhibition in patients with acute or chronic coronary syndrome undergoing complex PCI?
Cangrelor provides rapid platelet inhibition during complex PCI, but clinicians must be cautious of a potential rebound effect when transitioning to oral P2Y12 inhibitors.
Answers are grounded in this paper and cite their sources.
May benefit complex PCI via rapid cangrelor inhibition; hypothesis-generating with rebound caution, needs RCTs before practice change.
The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (ClincalTrials.gov: NCT04790032) is a prospective study conducted at Federico II University of Naples enrolling all patients undergoing PCI with cangrelor. Pharmacodynamic data show that cangrelor might be a useful option for a fast platelet inhibition during complex PCI, but caution should be paid to a potential rebound effect at the end of its infusion while the oral P2Y12 effect is not yet achieved.
No takes yet. Share an insight, caveat, or question.
Gargiulo et al. (2023) conducted a cohort in Acute or chronic coronary syndrome undergoing percutaneous coronary intervention. Cangrelor was evaluated on Pharmacodynamic effects (platelet inhibition and rebound effect). Cangrelor provides fast platelet inhibition during complex PCI, but may cause a potential rebound effect at the end of its infusion before the oral P2Y12 effect is achieved.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: